American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting

描述(申请人提供)：美国基因与细胞治疗学会(ASGCT)成立于1996年。ASGCT的使命是促进知识、意识和教育，从而发现和临床应用基因和细胞疗法来缓解人类疾病。我们的年会代表了协会的主要教育倡议，并在我们之前的14次会议中都获得了CME认证。这份R13提案要求为受训人员提供旅费补助。我们超过1/4的成员是实习科学家 致力于开发临床适用的基于基因的技术。学员参加年会是由杰出的教育项目、学员旅行奖励以及通过同行评审的学员卓越研究奖来表彰杰出的科学成就而促成的。在过去的十年中，ASGCT提供了470项旅行补助金和63项研究奖，其中近190项旅行补助金是在同一时期由NIH颁发的R13补助金提供的。旅行奖获得者的教育机会包括杰出的全体演讲者、最先进的科学研讨会，以及审查各种主题当前思维的教育会议。除了顶尖的科学家和临床医生，该项目还包括伦理学家和来自FDA、OBA和NIH的代表，因此年轻科学家可以深入了解与人类基因治疗和细胞治疗相关的合规和伦理问题。受训人员是口头摘要和海报演示的活跃演讲者，顶级受训人员摘要在总统座谈会上得到认可。ASGCT会议的规模(约1700名与会者)非常适合让年轻科学家接触该领域的领导者，同时为受训人员提供在基因和细胞治疗领域的首要会议上展示他们的工作的机会。NIH对ASGCT年会的支持将使细胞和基因治疗领域的受训人员继续获得教育和专业上的进步，并有机会与该领域的领导者建立网络联系。 与公共健康相关：美国基因与细胞治疗学会(ASGCT)正在为为其2012年5月第15届年会提交科学摘要的博士后研究员和学生提供20项旅行奖励而寻求资金。旅行奖颁发给申请该奖项并在同行评审过程中获得最高分的学生和博士后研究员。

DESCRIPTION (provided by applicant): The American Society of Gene & Cell Therapy (ASGCT) was founded in 1996. ASGCT's mission is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. Our Annual Meeting represents the major educational initiative of the Society and has been CME-accredited for all of our prior 14 meetings. This R13 proposal requests support for travel grants for trainees. Over 1/4 of our members are scientists-in-training working to develop clinically applicable gene- based technologies. Trainee participation in the Annual Meeting is fostered by an outstanding educational program, trainee travel awards, and recognition of outstanding scientific accomplishments through peer-reviewed trainee Excellence in Research Awards. Over the past decade, the ASGCT has offered 470 travel grants and 63 Research Awards, with almost 190 travel grants made possible by R13 grant awards from the NIH during that same time. Educational opportunities for travel awardees include exceptional plenary speakers, state-of-the-art scientific symposia, and educational sessions that review current thinking on a variety of topics. In addition to leading scientists and clinicians, the program includes ethicists and representatives from the FDA, OBA, and NIH so young scientists may gain insight into the compliance and ethical issues related to human gene therapy and cell therapy. Trainees are active presenters in oral abstract and poster presentations, and the top trainee abstracts are recognized at the Presidential Symposium. The size of the ASGCT meeting (approximately 1,700 participants) is ideally suited to expose young scientists to leaders in the field yet provide opportunities for trainees to present their work at the premier meeting in the field of gene and cell therapy. NIH support for the ASGCT Annual Meeting will allow continued educational and professional advancement of trainees in the field of cell and gene therapy and the opportunity to network with leaders in the field. PUBLIC HEALTH RELEVANCE: The American Society of Gene & Cell Therapy (ASGCT) is seeking funding for 20 travel awards for post-doctoral fellows and students who submit scientific abstracts for its 15th Annual Meeting in May 2012. Travel awards are given to students and post-doctoral fellows who apply for the awards and who receive the highest scores during the peer review process.